Semaglutide in Dubai
Research-grade GLP-1 receptor agonist. STEP trial data, branded vs research-grade comparison, titration protocols, and next-generation alternatives available in the UAE.
Semaglutide is a GLP-1 receptor agonist that demonstrated ~15% mean body weight reduction in STEP trials. It is the active molecule in Ozempic (diabetes) and Wegovy (weight management). In Dubai, branded semaglutide faces persistent supply shortages. Research-grade semaglutide is available for laboratory use, though researchers are increasingly studying next-generation compounds like retatrutide (24.2% weight loss) that offer superior efficacy through multi-receptor agonism.
Retatrutide pen 30mg (triple agonist, 24.2% weight loss data). 99.262% HPLC purity. 2-hour Dubai delivery.
What Is Semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. It mimics the naturally occurring incretin hormone GLP-1, which regulates appetite, blood sugar, and gastric emptying. Semaglutide’s key innovation is a fatty acid chain modification that extends its half-life to approximately 7 days, enabling once-weekly dosing.
It is marketed under three brand names: Ozempic (type 2 diabetes, injectable), Wegovy (chronic weight management, injectable at higher dose), and Rybelsus (type 2 diabetes, oral tablet). All contain the same semaglutide molecule at different doses and delivery formats.
STEP Trial Weight Loss Data
The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program established semaglutide as a breakthrough weight loss compound:
- STEP 1: 2.4mg weekly → 14.9% mean body weight reduction over 68 weeks (vs 2.4% placebo)
- STEP 2: In patients with type 2 diabetes → 9.6% weight loss
- STEP 3: Combined with intensive behavioural therapy → 16.0% weight loss
- STEP 5: Extended 104-week data → 15.2% sustained weight loss
These results made semaglutide the first pharmacological treatment to consistently achieve >10% mean weight loss in large clinical trials. However, next-generation compounds have since surpassed this benchmark. For detailed comparison data, see our best obesity drug 2026 analysis.
Semaglutide Availability in Dubai
Branded Products: Ozempic & Wegovy
Branded semaglutide availability in Dubai has been intermittent since 2023 due to global manufacturing constraints. Ozempic pharmacy stock is unpredictable, with wait times of 2–6 weeks common. Wegovy availability is even more limited. Our Ozempic shortage guide details the causes and expected timeline for supply normalisation.
Research-Grade Semaglutide
Research-grade semaglutide is available in Dubai for in-vitro laboratory use. Unlike branded products, research-grade supply is not subject to pharmaceutical distribution constraints. Key advantages include HPLC purity verification, published COA documentation, and reliable availability. Contact Remy Peptides via WhatsApp for current pricing and formats.
Clinic Pricing vs Research-Grade
Dubai clinics prescribing semaglutide for weight loss typically charge AED 1,500–4,000+ per month, including consultation fees. Research-grade semaglutide for laboratory use is available at a fraction of this cost. See our GLP-1 UAE pricing guide for a complete cost breakdown.
Semaglutide vs Next-Generation Compounds
While semaglutide established the GLP-1 agonist category, multi-receptor compounds now show superior efficacy:
| Compound | Receptors | Weight Loss | Status |
|---|---|---|---|
| Semaglutide | GLP-1 only | ~15% | Approved (Ozempic/Wegovy) |
| Tirzepatide | GLP-1 + GIP | ~22.5% | Approved (Mounjaro/Zepbound) |
| Retatrutide | GLP-1 + GIP + glucagon | 24.2% | Phase 3 (TRIUMPH) |
The glucagon receptor component in retatrutide increases energy expenditure and hepatic lipid oxidation—metabolic effects semaglutide does not produce. For researchers studying GLP-1 mechanisms, retatrutide represents the current frontier of multi-agonist obesity research. See our detailed retatrutide vs semaglutide comparison.
Semaglutide Dosing & Titration
Published Titration Schedule (STEP Trials)
The FDA-approved Wegovy titration protocol escalates over 16 weeks:
- Weeks 1–4: 0.25 mg/week
- Weeks 5–8: 0.5 mg/week
- Weeks 9–12: 1.0 mg/week
- Weeks 13–16: 1.7 mg/week
- Week 17+: 2.4 mg/week (maintenance)
Gradual titration significantly reduces GI side effects (nausea, vomiting). For research protocol planning, use our protocol calculator. For a comprehensive side-effect analysis across GLP-1 compounds, see our Ozempic vs Mounjaro vs Wegovy side effects comparison.
Delivery Across the UAE
- Dubai: 2-hour delivery — all areas
- Abu Dhabi: Next-day delivery
- Sharjah & other emirates: Next-day delivery
All shipments use temperature-controlled packaging. Contact us via WhatsApp at +34 672 737 521 for ordering and availability.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and published clinical trial data. Read our editorial policy →
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Davies M, et al. Semaglutide 2.4 mg in Patients with Type 2 Diabetes (STEP 2). Lancet. 2021;397:971-984.
- Rubino DM, et al. Effect of Weekly Semaglutide vs Daily Liraglutide (STEP 8). JAMA. 2022;327(2):138-150.
- Jastreboff AM, et al. Retatrutide Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
Retatrutide Pen 30 mg
Next-generation triple agonist. 24.2% weight loss data. 99.262% HPLC purity. 2-hour Dubai delivery.
Order Retatrutide Pen →